Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: Randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as
Highlights
► RCT testing behavioral weight loss and orlistat for obesity with and without binge eating. ► Educationally- and economically-disadvantaged Spanish-speaking-only Latino/as with mental health needs. ► Adding orlistat to behavioral weight loss produced modest weight loss amongst non-binge-eaters. ► Comparable outcomes for behavioral weight loss for binge eating as documented in the efficacy literature.
Section snippets
Participants
Participants were a consecutive series of 79 monolingual (Spanish-speaking-only) obese Latino/as (65 females, 14 males) recruited from clinical teams and referrals at a community mental health center serving economically disadvantaged persons with mental health needs. This study enrolled participants from August 2007 through October 2009. This RCT was designed with the goal of obtaining a broadly clinically-relevant obese patient group (aged 21–65 years of age with body mass index (BMI) of 30
Randomization and progression through the study
Fig. 1 summarizes the progression of participants through the study treatments and assessments. Of the 79 randomized patients, 40 (n = 20 with BED, n = 20 without-BED) received orlistat-plus-BWL and 39 (n = 20 with BED, n = 19 without BED) received placebo-plus-BWL. Treatment completion rates by medication status did not differ significantly: 75% (n = 30 of 40) for orlistat-plus-BWL and 82% (n = 32 of 39) for placebo-plus-BWL (χ2(1) = .58, p = .45). Treatment completion rates by BED status did
Discussion
This study was a randomized double-blind placebo-controlled treatment study performed with Spanish-speaking-only obese Latino/as with versus without BED at a community mental health center serving educationally- and economically-disadvantaged patients with mental health needs. This study tested the acute effects of adding orlistat to BWL, tested the durability of outcomes through 6-month follow-up after completing treatments, and represents the first controlled prospective study of
Biomedical support disclosures
The authors report no commercial or biomedical industry support or conflicts of interest. This research was supported by a grant from the Donaghue Foundation (Dr. Grilo). Preparation of this paper was also supported, in part, by the National Institutes of Health grant K24 DK070052 (Dr. Grilo) No additional funding was received for the completion of this work.
References (47)
- et al.
Obesity among those with mental disorders: a National Institute of Mental Health meeting report
American Journal of Preventive Medicine
(2009) - et al.
Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized double-blind placebo-controlled trial
Biological Psychiatry
(2005) - et al.
The prevalence and correlates of eating disorders in the NCS replication
Biological Psychiatry
(2007) - et al.
Mind the gap: improving the dissemination of CBT
Behaviour Research and Therapy
(2009) - et al.
Disparities by ethnicity and socioeconomic status in the use of weight loss treatments
Journal of the National Medical Association
(2009) - et al.
Prevalence and correlates of eating disorders in Latinos in the United States
International Journal of Eating Disorders
(2007) - et al.
Binge eating disorder and night eating syndrome: a comparative study of disordered eating
Journal of Consulting and Clinical Psychology
(2005) - et al.
Application of cultural constructs in the care of first generation Latina/o clients in a community mental health setting
Journal of Psychiatric Practice
(2005) - et al.
Manual for the Beck depression inventory-II
(1996) - et al.
Responses to weight loss treatment among obese individuals with and without BED: a matched-study meta-analysis
Eating and Weight Disorders
(2007)